Advances in the Imaging of Pituitary Tumors by MacFarlane, J et al.
ARTICLE TITLE:  
Advances in the imaging of pituitary tumours 
AUTHOR NAMES AND DEGREES 
*James MacFarlane MRCP(UK)1, *Waiel A Bashari MSc MRCP(UK)1, *Russell Senanayake MSc 
MRCP(UK)1, Daniel Gillett MSc1,2, Merel van der Meulen BSc1, Andrew S Powlson MRCP(UK)1, 
Angelos Kolias PhD FRCS1,3, Olympia Koulouri PhD MRCP(UK)1, Mark Gurnell PhD FRCP1 
 
* These authors contributed equally to this work. 
AUTHOR AFFILIATIONS 
1Cambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Wellcome Trust-
MRC Institute of Metabolic Science, University of Cambridge, and National Institute for Health 
Research, Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Hills Road, Cambridge, 
CB2 0QQ, UK 
2Department of Nuclear Medicine, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 0QQ, UK 
3Department of Neurosurgery, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 0QQ, UK 
CORRESPONDING AUTHOR 
Professor Mark Gurnell, Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic 
Science, University of Cambridge, Box 289, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0QQ, 
UK.  
Tel: +44-1223-348739                        E-mail: mg299@medschl.cam.ac.uk 
DISCLOSURE STATEMENT 
The Authors have nothing to disclose. 
Funding sources: JM, WB, RS, DG, AK, OK and MG are supported by the Cambridge NIHR Biomedical 
Research Centre; this work was also supported by a project grant from the Evelyn Trust (WB, OK, MG). 
KEY WORDS 
Pituitary adenoma, MRI, PET/CT, 11C-methionine, Met-PET/MRCR  
KEY POINTS 
• MRI remains the primary modality for imaging pituitary tumours (pituitary adenomas, PA) 
• Conventional MR sequences provide sufficient information to guide management in the majority of 
patients, but can lack sensitivity and specificity for: (i) detection of microadenomas; (ii) identification 
of the site(s) of residual/recurrent disease following primary therapy 
• Alternative MR sequences may aid characterisation of specific tumour traits (e.g. tumoral 
consistency; presence of apoplexy; invasion of surrounding structures) 
• Several different radiotracers have been investigated for molecular imaging of pituitary tumours with 
varying success 
• 11C-methionine PET co-registered with volumetric (1mm slice) MRI (Met-PET/MRCR) can: 
– aid accurate localisation of micro/pico-adenomas of all PA subtypes 
– identify sites of recurrent or incompletely resected disease and distinguish from post-operative 
change (e.g. acromegaly, Cushing’s disease) 
– augment radiotherapy planning in selected cases 
SYNOPSIS 
In most patients with pituitary adenomas (PA) magnetic resonance imaging (MRI) is essential to guide 
effective decision-making. A combination of T1- (± gadolinium enhanced) and T2-weighted sequences 
are commonly employed and allow the location and extent of the adenoma to be determined. In some 
instances, supplementary MR sequences (e.g. diffusion weighted; FLAIR; MR angiography; MR 
elastography) may provide additional information to guide surgery. However, in an important subgroup 
of patients MRI findings are ‘negative’ or equivocal (e.g. with failure to reliably identify the site of a 
microadenoma or to distinguish postoperative change from residual/recurrent disease). In this setting, 
molecular (functional) imaging [e.g. 11C-methionine PET/CT coregistered with volumetric MRI (Met-
PET/MRCR)] may allow accurate localisation of the site of de novo or persistent disease to guide 
definitive treatment (e.g. surgery or radiosurgery). 
 




Pituitary adenomas (PA) are typically benign, slow-growing tumours of the adenohypophysis, which 
come to attention due to associated endocrine dysfunction (e.g. hyperprolactinaemia, hypercortisolism, 
acromegaly/gigantism, hypopituitarism) and/or mass effect (e.g. compression of the optic chiasm or 
cranial nerves in the wall of the cavernous sinus), or when they are discovered incidentally during cross-
sectional imaging of the brain performed for a separate indication1. 
 
Pituitary incidentalomas are a relatively common finding in the general population, with a large meta-
analysis of autopsy series suggesting a mean prevalence of 10.7% (range 1.5-31%)2. These findings 
are broadly consistent with magnetic resonance imaging (MRI) studies of the sella and parasellar 
regions, which identify abnormalities in as many as 10-38% of subjects in unselected cohorts3,4. The 
majority of these are microadenomas and most do not result in endocrine dysfunction5. In contrast, 
clinically relevant PA have been estimated to affect between 1:1064 and 1:1200 of the general 
population6,7. 
 
Modern management of pituitary adenomas is ideally overseen by a specialist multidisciplinary team 
comprising neuroendocrinology, neurosurgery/otolaryngology, neuroradiology, neuropathology, neuro-
ophthalmology and neuro-oncology8. Cross-sectional imaging [MRI and/or computed tomography (CT)] 
of the sella and parasellar regions is central to effective decision-making and may be the major 
determinant of whether a patient is offered surgery, radiotherapy, medical therapy or surveillance. For 
the majority of cases, MRI remains the primary imaging modality and distinguishes the adenoma from 
normal pituitary tissue and adjacent structures9,10. However, in a small but important subgroup of 
patients conventional pituitary imaging is not informative. For example, whilst incidentalomas are a 
common finding in the general population, paradoxically some functioning microadenomas (including 
30-40% of corticotroph adenomas) are not readily visualised on standard pituitary MR sequences11. 
Similarly, following transsphenoidal surgery (TSS), site(s) of residual or recurrent disease may not be 
evident or readily distinguished from post-treatment changes12. In these contexts, the decision then lies 
between ‘blind’ surgical (re-)exploration, long-term (in some cases life-long) medical therapy, 
radiotherapy or even a combination of approaches, each with their own limitations with respect to the 
likelihood and time to achieving disease control, risk of inducing hypopituitarism, and causation of other 
adverse effects.   
 
Accordingly, several novel approaches to pituitary imaging have been proposed, largely based around 
the deployment of alternative MR sequences and/or novel techniques for image analysis, with the aims 
of: (i) improving diagnostic resolution, (ii) informing pre-treatment planning and (iii) predicting likely 
responses to different therapeutic strategies. In addition, a role for molecular imaging, with its ability to 
confirm/localise sites of functioning active tumour, is gaining prominence and may be particularly 
valuable when cross-sectional imaging remains equivocal. Here, we consider how these advances 




MAGNETIC RESONANCE IMAGING 
 
In a patient in whom a pituitary adenoma (PA) is suspected, dedicated MRI of the sella and parasellar 
regions should be performed to confirm the site and size of the tumour and its relationship to 
surrounding important structures. CT may offer important supplementary information in some cases 
(e.g. defining the extent of bony erosion with larger tumours; confirming/excluding the presence of 
calcification), and modern thin slice CT is a reasonable alternative for those unable or unwilling to 
undergo MRI10. 
 
Standard clinical pituitary MRI 
Spin-echo (SE) pulse sequences are one of the earliest developed and still widely used of all MRI pulse 
sequences, and remain a cornerstone of modern pituitary imaging. Although practice varies from centre 
to centre, routine clinical pituitary MRI protocols [using a 1.5 Tesla (1.5T) or 3T scanner] typically 
include: 
- pre-contrast T1-weighted SE and T2-weighted fast SE (FSE) coronal and sagittal sections with 
thin slices (typically 2-3 mm) 
- post-contrast T1-weighted SE coronal and sagittal sections with thin slices 
The addition of axial images may also be helpful in some cases and allows for more complete evaluation 
of the posterior pituitary gland13.  
 
The normal anterior pituitary gland is isointense to grey matter on non-contrast T1- and T2-weighted 
SE/FSE sequences; the posterior lobe demonstrates high T1 signal, but is hypointense on T2. Following 
injection of contrast, the infundibulum and gland progressively enhance (homogeneously). Contrast 
uptake by pituitary adenomas is typically slower, resulting in delayed enhancement and washout10,14.  
 
For cases without a clear abnormality on MRI, but in whom a lesion is strongly suspected on clinical 
grounds (e.g. ACTH-dependent Cushing’s syndrome with biochemical and/or petrosal sinus catheter 
evidence of a central origin), dynamic contrast-enhanced MRI (using T1-weighted sequences pre- and 
immediately post-contrast administration) may help identify the site of a microadenoma. However, 
gradient echo [e.g. spoiled gradient echo (SGE), (fast) spoiled gradient recalled echo (FSPGR/SPGR)], 
which allows imaging with a 1mm slice interval, has been suggested to offer greater sensitivity for 
localising microadenomas in the context of Cushing’s disease15,16. 
 
The most commonly employed contrast agent for pituitary imaging is gadolinium, a naturally-occurring 
lanthanide with strong paramagnetic properties (due to seven unpaired electrons). In its free form 
gadolinium is toxic and must therefore be chelated to a carrier ligand to permit safe clinical use. Recently 
however, concern has arisen regarding the potential for gadolinium deposition in the central nervous 
system even in patients with normal renal function17,18, which presents a particular challenge for pituitary 
endocrinologists and their patients given the often long-term requirement for periodic surveillance 
imaging19. It is therefore important that the need for contrast enhancement is carefully considered 
whenever imaging of the sella and parasellar regions is requested. For example, in a patient with a 
well-defined intrasellar tumour remnant following primary surgery for a non-functioning PA, and which 
is well visualised on non-contrast MRI, the inclusion of post-gadolinium sequences is likely to add little 
to the clinical decision making process – if there are concerns regarding tumour enlargement on non-
contrast T1- and T2-weighted images the patient can be recalled for further assessment.  
 
Similarly, attention has recently been drawn to those clinical settings in which T2-weighted MRI can 
afford comparable or even superior information to that provided by T1-weighted post-contrast imaging20, 
thus potentially avoiding the need for initial and/or repeat gadolinium administration (Table 1) (Figure 
1). 
 
Insert Table 1 and Figure 1 here 
 
Alternative pituitary MR sequences/techniques 
An increasing array of MR sequences have been adapted for use in pituitary disease. In addition, as 
the availability of higher field strength MRI systems (e.g. 7T) increases, potential applications in patients 
with PA are being increasingly explored. Currently, most of these approaches remain outside standard 
clinical protocols for imaging of the sella and parasellar regions, but may be requested when 
conventional sequencies leave important questions unanswered. These can be broadly considered 
under three categories (Table 2). 
A) As an aid to diagnosis 
B) To help inform preoperative assessment 
C) To predict likely treatment outcomes. 
 
Insert Table 2 here 
 
Advances in image analysis 
Novel approaches to image analysis are also being translated from other disease areas, allowing 
additional information to be derived from existing pituitary MR protocols. For example, in a study of 89 
patients who had undergone transsphenoidal surgery (TSS), and for whom the tumour Ki-67 
proliferation index was available, machine learning analysis of texture-derived parameters from 
preoperative T2-weighted MRI allowed prediction of which tumours would exhibit a high Ki-67 labelling 
index21. The adoption of a machine learning approach to the analysis of T2-weighted MRI has also 
been proposed as a means of evaluating macroadenoma consistency (and hence potential ease of 
resection) prior to surgery22. If substantiated in larger studies, wider roll-out of automated image 
analysis techniques could enable a more personalised approach to initial management and follow-up, 
using protocols for image acquisition that are already well established in most centres. 
 
 
MOLECULAR (FUNCTIONAL) IMAGING 
 
Molecular (functional) imaging is an important facet of the diagnostic pathway for several endocrine 
disorders: e.g. technetium 99m (99mTc)-pertechnetate scintigraphy in hyperthyroidism; 99mTc-sestamibi 
scintigraphy/single photon emission computed tomography (SPECT) in hyperparathyroidism; Indium-
111 (111In)-pentetreotide scintigraphy/SPECT or Gallium-68 (68Ga)-DOTATATE positron emission 
tomography (PET)/CT in neuroendocrine tumours (NETs). In addition to identifying the cause / 
localising sites of abnormal functioning tissue, in some instances it can also inform treatment decisions 
[e.g. use of Lutetium-177 (177Lu)-DOTATATE therapy in patients with metastatic NETs]. 
 
In contrast, molecular imaging has not traditionally been considered part of the diagnostic 
armamentarium for de novo or recurrent pituitary adenomas. Although several groups have explored 
tracers targeting different cellular pathways and receptor expression, the limitations associated with 
imaging the sella and parasellar regions using scintigraphy or CT have proved a significant challenge 
for both accurate PA localisation and discrimination of tumour from remaining normal pituitary tissue. 
However, several recent advances, including coregistration of high resolution PET-CT with volumetric 
(1 mm slice) MRI (PET/MRCR) and the advent of PET/MR scanners, have allowed for more accurate 
localisation of the site(s) of tracer uptake and differentiation from physiological uptake by the remaining 
normal pituitary gland. 
 
Somatostatin receptor imaging 
Earlier attempts at imaging pituitary adenomas using tracers targeting somatostatin receptors faltered 
on several counts, including the relatively poor spatial resolution of scintigraphy (even when combined 
with SPECT), variable somatostatin receptor (SSTR) expression of individual tumours, and competing 
background uptake by normal pituitary tissue. More latterly, studies using 68Ga-DOTATATE and 68Ga-
DOTATOC have shown greater promise, benefiting from the significantly improved spatial resolution 
offered by PET. Intriguingly, in one study lower tracer uptake was observed in clinically non-functioning 
PA (7 SF-1 and 2 T-Pit staining tumours) when compared with normal pituitary gland23. Moreover, 
comparing and contrasting appearances from 68Ga-DOTATATE PET with those of 18F-
fluorodeoxyglucose (18F-FDG)-PET has been proposed as a means of differentiating recurrent/residual 
pituitary adenoma from normal pituitary tissue24,25, and may also inform decision-making for aggressive 
pituitary tumours26,27. 
 
Dopamine receptor imaging 
Prolactin secretion from normal lactotrophs is subject to tonic dopaminergic inhibition, which is 
predominantly mediated by the dopamine receptor subtype 2 (D2R) 28. Although several high-affinity 
ligands for the D2 receptor, which have been used for PET imaging in other clinical contexts (e.g. 
psychiatric disorders), have been deployed for imaging PA29,30, to date they have failed to find a role in 
routine pituitary practice. In part, this likely reflects the relatively limited utility of functional imaging in 
tumours which are predominantly managed medically, with a high expectation of dopamine agonist 
sensitivity. In contrast, in acromegaly, where only approximately one in four somatotroph adenomas 
respond to dopamine agonist therapy, a functional imaging modality capable of predicting response to 
treatment (as reflected by focal PET tracer uptake) could represent a useful addition to the diagnostic 
algorithm when considering which patients might benefit from a trial of dopamine agonist for persistent 
residual disease. 
 
Fluorine-18 (18F)-FDG PET 
18F-fluorodeoxyglucose (18F-FDG) is a well-established PET tracer which finds widespread use in 
clinical oncology. Importantly, in a large retrospective study, which assessed pituitary uptake in 40,967 
subjects undergoing 18F-FDG PET/CT for other indications, focal increased tracer uptake in the pituitary 
fossa was observed in just 0.073% of cases, several of whom were subsequently shown to have 
pituitary adenomas 31; in a second study with a smaller sample size (13,145 subjects), incidental 
pituitary uptake was noted in 0.8% of subjects, although a significant proportion of these were not 
confirmed to represent pathological uptake on subsequent assessment 32. Together, these studies point 
to a likely low risk of false positive scans (<1%) and highlight the importance of referral for endocrine 
assessment in any patient with incidentally detected pituitary 18F-FDG uptake. In keeping with this, the 
literature contains numerous examples of different pituitary adenoma subtypes discovered incidentally 
during 18F-FDG PET/CT [non-functioning PA33,3435, prolactinoma 36, gonadotropinoma 37, 
somatotropinoma 38,39 and corticotropinoma 40].  
 
A role for 18F-FDG PET in the detection of de novo and residual/recurrent PA has been explored by 
several groups. In a prospective study of 24 patients with different subtypes of PA, all macroadenomas 
(n=14) and half of microadenomas (n=5) demonstrated increased tracer uptake 41. As outlined 
previously, 18F-FDG PET may also help distinguish residual or recurrent adenoma from remaining 
normal pituitary tissue following transsphenoidal surgery when combined with 68Ga-DOTATATE PET 
24.  
 
However, perhaps the greatest interest in the application of 18FDG PET in the management of pituitary 
disease has been in the field of Cushing's disease, where 30-40% of microadenomas may go 
unidentified on standard clinical MRI. In a study of 12 patients with pituitary Cushing’s 18F-FDG PET 
was found to be comparable to MRI for the localisation of corticotroph adenomas with a detection rate 
of approximately 60%, albeit without complete overlap between the two imaging modalities 42. In a 
prospective study of 10 patients with Cushing’s disease, Chittiboina and colleagues were able to show 
slight superiority of 18F-FDG PET in comparison with conventional spin-echo (SE) MRI but, in the same 
cohort, spoiled gradient recalled echo (SPGR) MRI was superior to 18FDG PET 43. However, more 
recently the same group has shown that prior stimulation with corticotropin-releasing hormone (CRH) 
may enhance the ability of 18F-FDG PET to detect corticotropinomas 44. 
 
Nitrogen-13 (13N)-Ammonia PET 
13N-ammonia has previously been proposed as a marker of pituitary gland perfusion and metabolism, 
which allows the localisation of normal functioning tissue, with reduced/absent uptake following pituitary 
injury 45. Perhaps mirroring this, in a single study of 13N-ammonia PET/CT in 48 patients with different 
PA subtypes (22 NFPA, 12 acromegaly, 10 Cushing’s disease, four prolactinomas), higher tracer 
uptake was observed in normal residual pituitary tissue compared to adenoma (which contrasted with 
findings on 18F-FDG PET/CT)  46. However, the ability of 13N-ammonia PET/CT to identify the site of 
normal pituitary tissue was diminished when the maximal tumour diameter exceeded 2 cm46. 
 
Fluorine-18 (18F)-Choline 
18F-Choline, a PET tracer employed in the staging and re-staging of prostate cancer, is taken up by the 
normal pituitary gland 47,48, raising the possibility of a role in imaging pituitary adenomas. However, to 
date, support for such a role is  limited to a small number of case reports of incidentally detected pituitary 
macroadenomas 49,50. It is also unclear whether uptake in pituitary adenomas is dependent on cellular 
proliferation (with incorporation into cell membranes), or reflects other aspects of choline 
transport/metabolism, as has been proposed for other well-differentiated endocrine tumours51. 
 
Carbon-11 (11C)-methionine 
The hallmark of pituitary adenomas is inappropriate peptide synthesis, even in clinically non-functioning 
tumours of the gonadotrope (SF-1) lineage. Accordingly, molecular imaging using a labelled amino acid 
PET tracer has the immediate attraction of potentially finding application in all PA subtypes. To date, 
the most studied amino acid tracer in PA is 11C-methionine, which benefits from considerably lower 
brain uptake (producing a more favourable target-to-background ratio), and increased sensitivity for the 
detection of PA, when compared with 18F-FDG52–54. 
 
Perhaps the single most important recent advance in pituitary imaging using 11C-methionine has been 
the move to routine co-registration of PET/CT and MRI images (Met-PET/MRICR), which allows (i) more 
accurate (anatomical) localisation of the site(s) of methionine uptake, and (ii) more reliable distinction 
between tumoral and normal pituitary tissue tracer uptake12,54–56; the advent of PET/MR hybrid scanners 
will likely further capitalise on these advances.  
 
As with other functional imaging modalities, biochemical assessment of disease status should be 
performed on the day of the 11C-methionine scan. In addition, patients treated with agents that suppress 
tumour function require a period of medication washout prior to imaging (e.g. 3 months for SSA therapy; 
4 weeks for DA therapy).  
 
Currently, there are two main clinical scenarios when Met-PET/MRICR should be considered: 
 
A) In de novo pituitary disease when targeted intervention (e.g. transsphenoidal surgery or 
stereotactic radiosurgery) is being considered, but MRI is either ‘negative’ or equivocal  
  
B) In patients with persistent/recurrent disease following previous intervention (surgery ± 
radiotherapy/radiosurgery ± medical therapy), when further targeted intervention would be 
considered but MRI is unable to reliably identify the site(s) of residual/recurrent disease and/or 
distinguish from post-treatment change. 
 
Patients in group A include up to 30% of patients with Cushing’s disease (Figure 2), occasional patients 
with acromegaly due to an occult microadenoma (Figure 3), some thyrotropinomas, and a small group 
of prolactinomas with dopamine agonist resistance and/or intolerance57,58. 
 
Insert Figures 2 and 3 here 
 
While all PA subtypes may be represented in group B, persistence/recurrence of hypercortisolism or 
acromegaly are the most common reasons for referral to our centre for Met-PET/MRICR (Figures 4 & 
5)12,57. Importantly, a significant proportion of patients with acromegaly who were previously deemed 
unsuitable for further surgical intervention can be offered a second or even third transsphenoidal 
approach following Met-PET/MRICR with the expectation of achieving full remission or a significant 
improvement in disease control12. More recently, we have also shown that subjects with suspected 
lateral sellar/parasellar disease may derive particular benefits from such an approach (Bashari et al, 
2020, in press). 
 





For the majority of patients diagnosed with a pituitary adenoma, good quality T1- (± contrast 
enhancement) and T2-weighted MRI sequences will provide all of the information that is required to 
facilitate effective and timely decision-making. However, imaging of pituitary tumours is an evolving 
field, both in response to, and as a driver of, developments in surgical, radiotherapeutic and 
pharmacological management strategies. Increasing use of alternative MR sequences may aid 
localisation of small functional tumours. Advances in analysis of MRI characteristics have the potential 
to predict tumour type and response to medical treatment. Molecular (functional) imaging, most clearly 
demonstrated to date with 11C-methionine PET (Met-PET/MRCR), is potentially able to facilitate curative 
surgery/radiotherapy (with minimum disruption of normal pituitary function) in an increasing number of 
scenarios, in both de novo and residual/recurrent pituitary disease. Molecular imaging may also be an 
aid in predicting response to specific medical therapies. In an era of personalised, precision medicine, 
imaging has an important, and increasing role in decision-making in pituitary disease.
 11 
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TABLE 1. UTILITY OF T2-WEIGHTED MR SEQUENCES IN PITUITARY IMAGING 
 
T2-WEIGHTED MRI 
APPEARANCE DIFFERENTIAL DIAGNOSIS References 
Hypointense  Rathke’s cleft cyst 
Hypointensity observed in one third of cases, although hypointense 
intracystic nodules are present in up to 70% of cases which are virually 
pathognomonic.   
 
GH-secreting PA (>50%)  
Hypointensity typically associated with:  
- Smaller tumours 
- Lower tendency to CSI 
- Greater SSA responsiveness 
 
Prolactinoma 
Hypointensity seen in a subset of cases (up to 20%, especially in men); 
unclear whether this predicts resistance to DA therapy; may indicate 































E.g. lymphocytic/autoimmune, immunotherapy-related or IgG-4 
disease 
 
Rathke’s cleft cyst 
Hyperintensity observed in 70% of cases. 
 
Prolactinoma (especially microadenomas) 
In general, degree of hyperintensity does not reliably predict response 




Hyperintensity/isointensity associated with: 
larger tumours 
greater tendency to CSI 



















Silent corticotroph (macro)adenoma (SCA) 
Multiple microcysts (small areas of high-intensity signal covering at 





Key: CSI, cavernous sinus invasion; DA, dopamine agonist; GH, growth hormone; IgG-4, 
immunoglobulin subtype-4; MRI, magnetic resonance imaging; PA, pituitary adenoma; SSA, 
somatostatin analogue therapy. 
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TABLE 2. ALTERNATIVE MR SEQUENCES/TECHNIQUES FOR PITUITARY IMAGING   
 
INDICATIONS MR SEQUENCE/TECHNIQUE References 
A: Aid to diagnosis 
Distinguish normal pituitary 
gland from PA or cyst 
Magnetic resonance spectroscopy (MRS) 
Golden-angle radial sparse parallel MRI (GRASP) 
63–65 
Distinguish PA from vascular 
lesions (e.g. aneurysm, 
meningioma) 
Magnetic resonance angiography (MRA) 66 
 
Perfusion weighted imaging (PWI) 67,68 
 
Detection of apoplexy and 
cystic lesions 
Diffusion weighted imaging (DWI)  69,70 
Localisation of corticotroph 
tumours 
 
7T (ultra-high field) MRI 
Fluid Attenuation Inversion Recovery (FLAIR) 
Constructive interference in steady state (CISS*) 
71–74 
 
B: Preoperative assessment 
 
Assessment of tumour 
consistency 
 
Contrast-enhanced Fast Imaging Employing Steady-state 
Acquisition (FIESTA) 
 
Magnetic resonance elastography (MRE) 






Assessment of tumour 
vascularity 
Perfusion weighted imaging (PWI) 84 
Delineation of cavernous sinus 
structures / tumour invasion 
Magnetic resonance angiography (MRA) 85,86 
 
Delineation of visual pathways 
(including optic nerve 
tractography)  
Contrast-enhanced Fast Imaging Employing Steady-state 
Acquisition (FIESTA) 
3D-constructive interference in steady state (CISS*) 






C: Prediction of treatment outcome 
 
Response to SSA therapy Magnetic resonance spectroscopy (MRS) 92 
Visual outcomes following 
pituitary surgery 
Diffusion tensor imaging (DTI) 91 
 
Successful tumour resection at 
TSS 
Apparent diffusion coefficient (ADC – a subtype of DWI) 80,93 
 
Key: 7T, 7 Tesla; MRI, magnetic resonance imaging; SSA, somatostatin analogue therapy; TSS, 






Fig 1. Prediction of pituitary tumour phenotype based on T2-weighted MRI appearances. A-C, 
T1 SE (pre- and post-contrast) and T2 FSE MRI in a patient with acromegaly, demonstrating a right-
sided macroadenoma; the tumour is hypointense on T2 sequences when compared to the adjacent 
temporal lobe, which has been linked with somatostain analogue responsiveness and a densely 
granulated appearance on histology. D-I, T1 SE (pre- and post-contrast) and T2W FSE MRI showing a 
macroadenoma with suprasellar extension in a patient who presented with visual loss, but no clinical or 
biochemical features of hypercortisolism; the tumour exhibits multiple microcysts (focal small areas of 
high intensity) on the T2 images. Key: FSE, Fast Spin Echo; Gad, gadolinium; SE, Spin Echo; T1, T1-
weighted; T2, T2-weighted. 
 
Fig 2. Identification of the site of an occult microadenoma in Cushing’s Disease. A-B, T1 SE MRI 
is unable to identify a discrete adenoma. C-D. Volumetric (FSPGR) MRI is also equivocal, but raises 
the possibility of a subtle area of hypoattenuation in the left side of the gland (yellow arrow). E-F, Met-
PET/MRCR demonstrates focal increased tracer uptake (yellow arrow) corresponding to the area seen 
on volumetric MRI (and subsequently confirmed at transsphenoidal surgery); normal physiological 
tracer uptake is seen in the right side of the gland (white arrow). Key: FSPGR, Fast Spoiled Gradient 
Recalled Echo; Gad, gadolinium; Met-PET/MRCR, 11C-methionine PET/CT coregistered with FSPGR 
MRI; SE, Spin Echo; T1, T1-weighted.  
 
Fig 3. Identification of the site of an occult microadenoma in acromegaly. A-B, T1 SE MRI 
demonstrates equivocal findings with no discrete adenoma visualised. C-D, Volumetric (FSPGR) MRI 
identifies a 5mm focal hypointensity in the right inferior aspect of the gland (yellow arrow) suggestive of 
a microadenoma. E-F, Met-PET/MRCR reveals an area of focal high tracer uptake (yellow arrow) at the 
site of the suspected microadenoma. Key: FSPGR, Fast Spoiled Gradient Recalled Echo; Gad, 
gadolinium; Met-PET/MRCR, 11C-methionine PET/CT coregistered with FSPGR MRI; SE, Spin Echo; 
T1, T1-weighted. 
 
Fig 4. Localisation of the site of early recurrence (at 8 months) following primary surgery in a 
patient with acromegaly (sparsely granulated tumour; MIB-1 proliferation index =15%).  A-B, T1-
SE MRI shows a largely empty sella, but with a possible area of abnormal tissue posterior to the site of 
insertion of the infundibulum (yellow arrow). C-D. Volumetric (FSPGR) MRI demonstrates a similar 
appearance. E-F, Met-PET/MRCR shows focal high tracer uptake at the suspected site of recurrence 
(confirmed at repeat transsphenoidal surgery). Key: FSPGR, Fast Spoiled Gradient Recalled Echo; 
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Gad, gadolinium; Met-PET/MRCR, 11C-methionine PET/CT coregistered with FSPGR MRI; SE, Spin 
Echo; T1, T1-weighted. 
 
Fig 5. Localisation of the site of late recurrence (at 48 months) following primary surgery in a 
patient with Cushing’s Disease.  A-B. T1-SE MRI demonstrates an area of hypointensity adjacent to 
(yellow arrow), and possibly invading (yellow dashed arrow), the left cavernous sinus. C-D. Volumetric 
(FSPGR) MRI suggests the area of abnormal signal lies medial to the cavernous sinus.  E-F, Met-
PET/MRCR shows focal high tracer uptake that corresponds with the findings of FSPGR MRI (confirmed 
at repeat transsphenoidal surgery with complete postoperative biochemical remission); normal 
physiological tracer uptake is seen in the right side of the gland (white arrow).  Key: FSPGR, Fast 
Spoiled Gradient Recalled Echo; Gad, gadolinium; Met-PET/MRCR, 11C-methionine PET/CT 
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